Nasal lavage fluid concentrations of eotaxin-1 (CCL11) in naturally occurring allergic rhinitis: Relationship to disease activity, nasal luminal eosinophil influx, and plasma protein exudation

Clinical and Experimental Allergy

Volumn 35, Issue 8, 2005, Pages 995-1002

  Salib, Rami J ^a,b   Lau, L C ^a   Howarth, P H ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

2 macroglobulin; Allergic rhinitis; Cytospins; ELISA; Eosinophil; Eotaxin; Nasal lavage; Naturally occurring disease

Indexed keywords

ALPHA 2 MACROGLOBULIN; EOTAXIN; PLASMA PROTEIN;

ADULT; ARTICLE; BLOOD VESSEL PERMEABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAY FEVER; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; MALE; NOSE MUCUS; PATHOGENESIS; PERENNIAL RHINITIS; PHENOTYPE; PRIORITY JOURNAL; VOLUNTEER;

ADULT; ALPHA-MACROGLOBULINS; BIOLOGICAL MARKERS; CAPILLARY PERMEABILITY; CHEMOKINES, CC; CHEMOTACTIC FACTORS, EOSINOPHIL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EOSINOPHILS; FEMALE; HUMANS; LEUKOCYTE COUNT; MACROPHAGES; MALE; MIDDLE AGED; NASAL LAVAGE FLUID; NEUTROPHILS; RESPIRATORY HYPERSENSITIVITY;

EID: 27744574230     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2005.02236.x     Document Type: Article

References (64)

1. Howarth PH. Allergic and nonallergic rhinitis. In: Adkinson NF, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER, eds. Middleton's allergy. Principles and practice, 6th Edn. Philadelphia: Mosby, 2003; 1391-410.
2. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996; 2:449-56.
3. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997; 277:2005-7.
4. Heath H, Qin S, Rao P et al. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997; 99:178-84.
5. Uguccioni M, Mackay CR, Ochensberger B et al. High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J Clin Invest 1997; 100:1137-43.
6. Romagnani P, De Paulis A, Beltrame C et al. Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines. Am J Pathol 1999; 155:1195-204.
7. Pipkorn U. Hay fever: in the laboratory and at natural allergen exposure. Allergy 1988; 43 (Suppl. 8):41-4.
8. Ganzalo JA, Jia GQ, Aguirre V et al. Mouse eotaxin expression parallels eosinophil accumulation during lung allergic inflammation but it is not restricted to a Th2-type response. Immunity 1996; 4:1-14.
9. Gonzalo JA, Lloyd CM, Kremer L et al. Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors. J Clin Invest 1996; 98:2332-45.
10. Rothenberg ME, MacLean JA, Pearlman E, Luster AD, Leder P. Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J Exp Med 1997; 185:785-90.
11. Teixeira MM, Wells TN, Lukacs NW et al. Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin. J Clin Invest 1997; 100:1657-66.
12. Gonzalo JA, Lloyd CM, Wen D et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med 1998; 188:157-67.
13. Hanazawa T, Antuni JD, Kharitonov SA, Barnes PJ. Intranasal administration of eotaxin increases nasal eosinophils and nitric oxide in patients with allergic rhinitis. J Allergy Clin Immunol 2000; 105:58-64.
14. Gorski P, Wittczak T, Walusiak J et al. Eotaxin but not MCP-3 induces eosinophil influx into nasal fluid in allergic patients. Allergy 2002; 57:519-28.
15. Terada N, Hamano N, Kim WJ et al. The kinetics of allergen-induced eotaxin level in nasal lavage fluid: its key role in eosinophil recruitment in nasal mucosa. Am J Respir Crit Care Med 2001; 164:575-9.
16. Greiff L, Petersen H, Mattsson E et al. Mucosal output of eotaxin in allergic rhinitis and its attenuation by topical glucocorticosteroid treatment. Clin Exp Allergy 2001; 31:1321-7.
17. Meyer P, Andersson M, Persson CG, Greiff L. Steroid-sensitive indices of airway inflammation in children with seasonal allergic rhinitis. Pediatr Allergy Immunol 2003; 14:60-5.
18. Salib RJ, Kumar S, Wilson SJ, Howarth PH. Nasal mucosal immunoexpression of the mast cell chemoattractants TGF-beta, eotaxin, and stem cell factor and their receptors in allergic rhinitis. J Allergy Clin Immunol 2004; 114:799-806.
19. Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104:927-33.
20. Belda J, Parameswaran K, Keith PK, Hargreave FE. Repeatability and validity of cell and fluid-phase measurements in nasal fluid: a comparison of two methods of nasal lavage. Clin Exp Allergy 2001; 31:1111-5.
21. Salib RJ, Salagean M, Lau L et al. The anti-inflammatory response of anti-eotaxin monoclonal antibody CAT-213 on nasal allergen-induced cell infiltration and activation. J Allergy Clin Immunol 2003; 111:8347.
22. Pereira S, Clark T, Darby Y et al. Effects of anti-eotaxin monoclonal antibody CAT-213 on allergen-induced rhinitis. J Allergy Clin Immunol 2003; 111:8268.
23. Radinger M, Johansson AK, Sitkauskiene B, Sjostrand M, Lotvall J. Eotaxin-2 regulates newly produced and CD34 airway eosinophils after allergen exposure. J Allergy Clin Immunol 2004; 113:1109-16.
24. Howarth PH, Persson CGA, Meltzer EO, Jacobson MR, Durham SR, Silkoff PE. Objective monitoring of nasal airway inflammation in rhinitis. J Allergy Clin Immunol 2005; 115:8414-41.
25. Jacobson MR, Juliusson S, Lowhagen O, Balder B, Kay AB, Durham SR. Effect of topical corticosteroids on seasonal increases in epithelial eosinophils and mast cells in allergic rhinitis: a comparison of nasal brush and biopsy methods. Clin Exp Allergy 1999; 29:1347-55.
26. Beaulieu S, Robbiani DF, Du X et al. Expression of a functional eotaxin (CC chemokine ligand 11) receptor CCR3 by human dendritic cells. J Immunol 2002; 169:2925-36.
27. Seto H, Suzaki H, Shioda S. Immunohistochemical localization of eotaxin immunoreactivity in nasal polyps. Acta Otolaryngol 2004; 553 (Suppl.):99-104.
28. Ponath PD, Qin S, Ringler DJ et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 1996; 97:604-12.
29. Minshall EM, Cameron L, Lavigne F et al. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. Am J Respir Cell Mol Biol 1997; 17:683-90.
30. Pullerits T, Linden A, Praks L, Cardell LO, Lotvall J. Upregulation of nasal mucosal eotaxin in patients with allergic rhinitis during grass pollen season: effect of a local glucocorticoid. Clin Exp Allergy 2000; 30:1469-75.
31. Gratziou C, Rovina N, Lignos M, Vogiatzis I, Roussos C. Exhaled nitric oxide in seasonal allergic rhinitis: influence of pollen season and therapy. Clin Exp Allergy 2001; 31:409-16.
32. Martin U, Bryden K, Devoy M, Howarth P. Increased levels of exhaled nitric oxide during nasal and oral breathing in subjects with seasonal rhinitis. J Allergy Clin Immunol 1996; 97:768-72.
33. Kawamoto H, Takeno S, Yajin K. Increased expression of inducible nitric oxide synthase in nasal epithelial cells in patients with allergic rhinitis. Laryngoscope 1999; 109:2015-20.
34. al-Ali MK, Howarth PH. Nitric oxide and the respiratory system in health and disease. Respir Med 1998; 92:701-15.
35. Terada N, Hamano N, Nomura T et al. Interleukin-13 and tumour necrosis factor-alpha synergistically induce eotaxin production in human nasal fibroblasts. Clin Exp Allergy 2000; 30:348-55.
36. Li L, Xia Y, Nguyen A et al. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol 1999; 162:2477-87.
37. Nonaka M, Pawankar R, Fukumoto A, Ogihara N, Sakanushi A, Yagi T. Induction of eotaxin production by interleukin-4, interleukin-13 and lipopolysaccharide by nasal fibroblasts. Clin Exp Allergy 2004; 34:804-11.
38. Wenzel SE, Trudeau JB, Barnes S et al. TGF-beta and IL-13 synergistically increase eotaxin-1 production in human airway fibroblasts. J Immunol 2002; 169:4613-9.
39. Bradding P, Feather IH, Wilson S, Holgate ST, Howarth PH. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am J Respir Crit Care Med 1995; 151:1900-6.
40. Bradding P, Mediwake R, Feather IH et al. TNF alpha is localized to nasal mucosal mast cells and is released in acute allergic rhinitis. Clin Exp Allergy 1995; 25:406-15.
41. Bradding P, Feather IH, Wilson S et al. Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation. J Immunol 1993; 151:3853-65.
42. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C. Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest 1997; 99:1492-9.
43. Cameron L, Hamid Q, Wright E et al. Local synthesis of epsilon germline gene transcripts, IL-4, and IL-13 in allergic nasal mucosa after ex vivo allergen exposure. J Allergy Clin Immunol 2000; 106:46-52.
44. Meltzer EO, Schaltz M, Ziger RS. Allergic and non-allergic rhinitis. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, eds. Allergy, principles and practice. St. Louis: Mosby, 1988; 1253-89.
45. Pipkorn U, Karlsson G. Methods for obtaining specimens from the nasal mucosa for morphological and biochemical analysis. Eur Respir J 1988; 1:856-62.
46. Naclerio R, Togias A, Flowers B et al. eds. Nasal lavage: a technique for elucidating the pathophysiology of allergic rhinitis. Copenhagen: Munksgaard, 1990.
47. Wilson SJ, Lau L, Howarth PH. Inflammatory mediators in naturally occurring rhinitis. Clin Exp Allergy 1998; 28:220-7.
48. Knani J, Campbell A, Enander I, Peterson CG, Michel FB, Bousquet J. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis. J Allergy Clin Immunol 1992; 90:880-9.
49. Kaszuba SM, Baroody FM, deTineo M, Haney L, Blair C, Naclerio RM. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med 2001; 161:2581-7.
50. Saengpanich S, deTineo M, Naclerio RM, Baroody FM. Fluticasone nasal spray and the combination of loratadine and montelukast in seasonal allergic rhinitis. Arch Otolaryngol Head Neck Surg 2003; 129:557-62.
51. Benson M, Reinholdt J, Cardell LO. Allergen-reactive antibodies are found in nasal fluids from patients with birch pollen-induced intermittent allergic rhinitis, but not in healthy controls. Allergy 2003; 58:386-92.
52. Benson M, Wennergren G, Fransson M, Cardell LO. Altered levels of the soluble IL-1, IL-4 and TNF receptors, as well as the IL-1 receptor antagonist, in intermittent allergic rhinitis. Int Arch Allergy Immunol 2004; 134:227-32.
53. Ahlstrom-Emanuelsson CA, Greiff L, Andersson M, Persson CG, Erjefalt JS. Eosinophil degranulation status in allergic rhinitis: observations before and during seasonal allergen exposure. Eur Respir J 2004; 24:750-7.
54. Svensson C, Andersson M, Persson CG, Venge P, Alkner U, Pipkorn U. Albumin, bradykinins, and eosinophil cationic protein on the nasal mucosal surface in patients with hay fever during natural allergen exposure. J Allergy Clin Immunol 1990; 85:828-33.
55. Andersson M, Svensson C, Andersson P, Pipkorn U. Objective monitoring of the allergic inflammatory response of the nasal mucosa in patients with hay fever during natural allergen exposure. Am Rev Respir Dis 1989; 139:911-4.
56. Greiff L, Andersson M, Svensson C et al. Effects of orally inhaled budesonide in seasonal allergic rhinitis. Eur Respir J 1998; 11:1268-73.
57. Meyer P, Persson CG, Andersson M et al. Alpha2-macroglobulin and eosinophil cationic protein in the allergic airway mucosa in seasonal allergic rhinitis. Eur Respir J 1999; 13:633-7.
58. Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000; 356:2144-8.
59. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167:199-204.
60. Montefort S, Holgate ST, Howarth PH. Leucocyte-endothelial adhesion molecules and their role in bronchial asthma and allergic rhinitis. Eur Respir J 1993; 6:1044-54.
61. Lee BJ, Naclerio RM, Bochner BS, Taylor RM, Lim MC, Baroody FM. Nasal challenge with allergen upregulates the local expression of vascular endothelial adhesion molecules. J Allergy Clin Immunol 1994; 94:1006-16.
62. Persson CG, Erjefalt JS, Greiff L et al. Plasma-derived proteins in airway defence, disease and repair of epithelial injury. Eur Respir J 1998; 11:958-70.
63. Howarth PH. Leukotrienes in rhinitis. Am J Respir Crit Care Med 2000; 161:8133-6.
64. Minnicozzi M, Duran WN, Gleich GJ, Egan RW. Eosinophil granule proteins increase microvascular macromolecular transport in the hamster cheek pouch. J Immunol 1994; 153:2664-70.